2. Search Result
Search Result
Results for "

CETP+Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-13327
    Evacetrapib
    3 Publications Verification

    LY2484595

    		 CETP Cardiovascular Disease
    Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
    Evacetrapib
  • HY-18778
    Obicetrapib

    TA-8995; DEZ-001; AMG-899

    		 CETP Apolipoprotein LPL Receptor LDLR Cardiovascular Disease
    Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib
  • HY-12090
    Anacetrapib
    3 Publications Verification

    MK-0859

    		 PCSK9 Cardiovascular Disease
    Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
    Anacetrapib
  • HY-12089
    Torcetrapib

    CP-529414

    		 CETP Endocrinology
    Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
    Torcetrapib
  • HY-14950
    Dalcetrapib
    2 Publications Verification

    JTT-705; RO4607381

    		 CETP Cardiovascular Disease Cancer
    Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively .
    Dalcetrapib
  • HY-116078
    CKD-519

    		CETP Cardiovascular Disease
    CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor, which inhibits CETP-mediated transfer of cholesteryl ester in human serum with an IC50 of 2.3 nM .
    CKD-519
  • HY-171883
    BI-5756

    		Cannabinoid Receptor CETP MHC Metabolic Disease Inflammation/Immunology Cancer
    BI-5756 is a CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. BI-5756 can significantly increase HDL-C levels and reduce LDL-C levels. BI-5756 can also enhance the function of regulatory T cells while maintaining T cell-mediated anti-tumor activity. BI-5756 can directly inhibit the growth of tumor cells and upregulate the expression of MHC I, MHC II, and CD80 on tumor cells. BI-5756 has a protective effect in graft-versus-host disease models. BI-5756 can be used in research on tumors, graft-versus-host disease, and metabolic diseases .
    BI-5756
  • HY-107997
    TAP311

    		CETP Cardiovascular Disease
    TAP311 is a cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 62 nM .
    TAP311
  • HY-123039
    CP-532623

    		CETP Metabolic Disease
    CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties .
    CP-532623
  • HY-105316
    CP-800569

    		CETP Metabolic Disease
    CP-800569 is an orally active cholesteryl ester transfer protein (CETP) inhibitor. CP-800569 can decrease low-density lipoprotein and postprandial triglyceride and increase high-density lipoprotein. CP-800569 can be used for the research of metabolic disease .
    CP-800569
  • HY-142643
    CETP-IN-4

    		CETP Metabolic Disease
    CETP-IN-4 is a cholesteryl ester transfer protein (CETP) inhibitor.
    CETP-IN-4
  • HY-13327R
    Evacetrapib (Standard)

    LY2484595 (Standard)

    		 CETP Reference Standards Cardiovascular Disease
    Evacetrapib (Standard) is the analytical standard of Evacetrapib. This product is intended for research and analytical applications. Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
    Evacetrapib (Standard)
  • HY-12090R
    Anacetrapib (Standard)

    MK-0859 (Standard)

    		 PCSK9 Reference Standards Cardiovascular Disease
    Anacetrapib (Standard) is the analytical standard of Anacetrapib. This product is intended for research and analytical applications. Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
    Anacetrapib (Standard)
  • HY-14950R
    Dalcetrapib (Standard)

    JTT-705 (Standard); RO4607381 (Standard)

    		 CETP Reference Standards Cardiovascular Disease Cancer
    Dalcetrapib (Standard) is the analytical standard of Dalcetrapib. This product is intended for research and analytical applications. Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively .
    Dalcetrapib (Standard)
  • HY-132303
    MK-8262

    		CETP Cardiovascular Disease Metabolic Disease
    MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research .
    MK-8262
  • HY-18778B
    Obicetrapib potassium

    TA-8995 potassium; DEZ-001 potassium; AMG-899 potassium

    		 Apolipoprotein CETP LPL Receptor LDLR Metabolic Disease
    Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib potassium
  • HY-18778A
    Obicetrapib sodium

    TA-8995 sodium; DEZ-001 sodium; AMG-899 sodium

    		 Apolipoprotein CETP LPL Receptor LDLR Cardiovascular Disease
    Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib sodium
  • HY-182320
    DRL-17822

    		CETP Cardiovascular Disease
    DRL-17822 is a selective cholesteryl ester transfer protein (CETP) inhibitor. DRL-17822 increases high-density lipoprotein levels. The exposure of DRL-17822 nanocrystal formulation increases significantly after a high-fat breakfast. The exposure of DRL-17822 in the fasted state is higher than that of its nanocrystal formulation. DRL-17822 can be used in the research of type II hyperlipidemia and atherosclerotic cardiovascular disease .
    DRL-17822

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: